Io­vance's $211M of­fer­ing; Almi­rall li­cens­es No­vo drug; As­traZeneca files Da­to-DXd; Sonata lay­offs

Plus oth­er news you may have missed from the FTC, Ever­est, Gilead, IsomAb, Oramed, In­novent, Sonata, Lari­mar and Im­munome.

Io­vance Bio­ther­a­peu­tics of­fers $211M in shares: The com­pa­ny is sell­ing more than 23 mil­lion shares for $9.15 each with the of­fer­ing ex­pect­ed to close on Feb­ru­ary 22. The cash should sup­port the launch of Io­vance’s T cell ther­a­py Am­tagvi, which was ap­proved Fri­day, and late-stage stud­ies of its pipeline drugs. — Ay­isha Shar­ma 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER